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Voltage-gated ion channels are important mediators of physiological functions in the
central nervous system.The cyclic activation of these channels inﬂuences neurotransmitter
release, neuron excitability, gene transcription, and plasticity, providing distinct brain
areas with unique physiological and pharmacological response. A growing body of data
has implicated ion channels in the susceptibility or pathogenesis of psychiatric diseases.
Indeed, population studies support the association of polymorphisms in calcium and
potassium channels with the genetic risk for bipolar disorders (BPDs) or schizophrenia.
Moreover, point mutations in calcium, sodium, and potassium channel genes have been
identiﬁed in some childhood developmental disorders. Finally, antibodies against potassium
channel complexes occur in a series of autoimmune psychiatric diseases. Here we
report recent studies assessing the role of calcium, sodium, and potassium channels
in BPD, schizophrenia, and autism spectrum disorders, and brieﬂy summarize promising
pharmacological strategies targeted on ion channels for the therapy of mental illness and
related genetic tests.
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INTRODUCTION
Important advances have been made in the diagnosis and treat-
ment of psychiatric disorders. A growing body of data, indeed,
supports the view that these disorders arise through the inter-
play of genetic (Askland et al., 2012; Devlin and Scherer, 2012;
Mulle, 2012; Sullivan et al., 2012) and environmental risk factors
(Karmiloff-Smith et al., 2012) and result from structural and func-
tional impairments in various brain regions such as thalamus,
amygdala, mid-brain, and the prefrontal cortex (Gargus, 2006;
Squintani et al., 2010; O’Donnell, 2012; Offord, 2012; Piper et al.,
2012; Price and Drevets, 2012; Stachowiak et al., 2013). More-
over, speciﬁc pattern of brain activity have been correlated to the
clinical phenotype of some mental disorders (Bigos et al., 2010).
Voltage-gated ion channels and inward rectiﬁer potassium chan-
nels are widely and selectively distributed in the brain, both in
neurons and astrocytes, often forming macromolecular complexes
with associated proteins or auxiliary subunits within distinct
subcellular compartments. The alternating activation of differ-
ent ionic currents sets the resting membrane potential, generates
the action potential, and regulates the neuronal ﬁring frequency
and neurotransmitter release, thus providing neuronal cells with
speciﬁc electrical identity (Hibino et al., 2010; Catterall, 2012;
Jan and Jan, 2012). Since the early 1990s, ion channel genes
have been mapped on human chromosomes and mutations in
these genes have been subsequently identiﬁed. Several neuro-
logical diseases such as epilepsy, episodic ataxias, migraine, due
to abnormal functioning of brain electrical circuits have been
attributed to ion channel mutations (Gargus, 2009; Kullmann,
2010; Imbrici et al., 2011). Therefore, it is not surprising that
alterations in ion channels activity in the relevant brain areas
may be also claimed in the etiopathology of psychiatric disorders
(Gargus, 2006, 2009; Liao and Soong, 2010; Askland et al., 2012;
O’Roak et al., 2012).
This review focuses on the emerging pathological role of
calcium, sodium, and potassium channels in bipolar disorder
(BPD), schizophrenia, and autism spectrum disorders (ASDs;
Table 1). Some neuropsychiatric syndromes of autoimmune ori-
gin will also be discussed. The involvement of neurotransmitter
operated ion channels, like nicotinic, glycine, GABA, and glu-
tamate receptors, is also well established in schizophrenia and
BPD, but is beyond the scope of this paper (for reviews, see
Gonzalez-Burgos et al., 2011; Benes, 2012; Egerton and Stone,
2012; Fountoulakis, 2012; Javitt, 2012). The contribution of ion
channels to the etiology of neuropsychiatric disorders can be
variable. Ion channels can be the unique cause of the disease,
as occurs in Timothy syndrome (TS), an autosomal dominant
disease caused by calcium channel mutations (Gargus, 2009).
In most cases, however, the association of ion channels genetic
variants with major psychiatric disorders is far more compli-
cated, due to the complex genetic architecture of these disorders.
Until recently in fact, information about the potential associa-
tion between psychiatric diseases and genetic predisposing factors
came from genome-wide association studies (GWAS) based on
a common disease/common variant (CD/CV) model, where the
disease resulted from the inheritance in any individual, of a com-
bination of several common variants, each contributing with
small effect (Mitchell and Porteous, 2011). However, the latest
ﬁndings demonstrate that major psychiatric disorders are also
caused by rare and often de novo mutations of large effect (Mulle,
2012; O’Roak et al., 2012). Furthermore, ion channels muta-
tions are often found in patients where epilepsy occurs together
with psychiatric symptoms, suggesting fundamental overlapping
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Table 1 | Ion channels involved in main neuropsychiatric disorders.
Ion channel
type/disease
Gene Protein Chromosome Pharmacological perspectives Reference
Calcium
Bipolar disorder,
schizophrenia, autism
spectrum disorders,
Timothy syndrome
CACNA1C Cav1.2 α
subunit
12p13.3 Cav channel blockers (verapamil,
nicardipine) as antipsychotics;
α2β4 ligands (pregabalin) as
antidepressants
Gargus (2009), International
Schizophrenia Consortium (2009),
Liao and Soong (2010), Lee et al.
(2012); Valente et al. (2012)
CACNG2,4,5 Calcium channel
γ subunits
22q13.1, 17q24 Wilson et al. (2006), Curtis et al. (2011)
CACNA2D4 Calcium channel
α2β4 subunit
12p13.3 Van Den Bossche et al. (2012)
Sodium
Autism spectrum
disorders/epilepsy,
Dravet syndrome
SCN1A Nav1.1 α
subunit
2q24.3 Nav channel blockers
(lamotrigine, phenytoin,
carbamazepine) as mood
stabilizers and antidepressants;
antidepressants (ﬂuoxetine,
sertraline) block Nav channels
Aldana and Sitges (2012); Bender et al.
(2012), O’Roak et al. (2012); Sanders
et al. (2012), Perucca and Mula (2013)
SCN2A Nav1.2 α
subunit
2q24.3 Chen et al. (2010), Bartnik et al. (2011),
Psychiatric GWAS Consortium Bipolar
DisorderWorking Group (2011),
Sanders et al. (2012)
SCN3A Nav1.3 α
subunit
2q24 Davidsson et al. (2008); Chen et al.
(2010)
Potassium
Bipolar disorder,
schizophrenia, autism
spectrum disorders,
autoimmune
neuropsychiatric
disorder
KCN1A Kv1.1 12p13.32 Kv1.1 “disinactivators” as
potential anticonvulsants and in
neuropathic pain
Lu et al. (2008), Illingworth et al.
(2011), Somers et al. (2011)
KCNQ3 Kv7.3 8q24 KCNQ openers (retigabine) as
anticonvulsant and antipsychotic
drugs; KCNQ inhibitors
(linopirdine) for learning
disabilities
Zhang et al. (2010a), Psychiatric GWAS
Consortium Bipolar DisorderWorking
Group (2011); Kristensen et al. (2012)
KCNH2 HERG1, Kv11.1 7q36.1 Atalar et al. (2010)
KCNJ3 Kir3.1 2q24.1 Yamada et al. (2012)
KCNJ10 Kir4.1 1q23.2 Selective serotonin reuptake
inhibitors (ﬂuoxetine,
escitalopram) and tricyclic
antidepressants (nortriptyline)
block Kir channels
Ohno et al. (2007); Sala-Rabanal et al.
(2010), Williams et al. (2010), Sicca
et al. (2011)
KCNJ8/KCNJ11 Kir6.1/Kir6.2 12p11.23/
11p15.1
KATP openers (diazoxide,
iptakalim) as antipsychotics
Sun et al. (2010); Mele et al. (2012)
KCNN3 SKCa3 (SK3) 1q21.3 SK3 openers for learning
difﬁculties and schizophrenia
Gargus (2006), Grube et al. (2011)
KCNMA1 KCa1.1 10q22.3 Laumonnier et al. (2006)
KCNK9 TASK3 8q24.3 Barel et al. (2008)
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etiology of apparently clinically distinct disorders (Derry et al.,
2008; Hermann et al., 2008; Sicca et al., 2011). Furthermore,
disease-modifying variants in each individual can account for
the phenotypic variability typical of mental illness (Mitchell,
2011). For some of these disorders a genetic test is available
(Table 2). The drugability of ion channels supports research efforts
to clarify the dynamics of ion channels contribution in func-
tional brain disorders, and to identify compoundswith therapeutic
potential.
GENERAL FEATURES OF ION CHANNELS
Voltage-gated ion channels are made up of one or more pore-
forming subunits (generally referred to asα subunits), and variable
numbers of accessory subunits (often denoted β, γ, etc.). The α
subunit is the ion-conducting pore determining the ion selectiv-
ity and the voltage-sensing functions of the channel. However,
the biophysical properties of native channels isolated from the
brain are determined by the presence of cytoplasmic or extracel-
lular modulatory auxiliary subunits (Jan and Jan, 2012; Weiss and
Zamponi, 2012). The α subunits of the voltage-gated potassium,
sodium, and calcium channels are all evolutionary related and
share a similar structure (Catterall, 2011; Eijkelkamp et al., 2012;
Zakon, 2012).
VOLTAGE-GATED CALCIUM CHANNELS
Voltage-gated calcium channels (Cav channels) mediate calcium
entry into a wide variety of electrically excitable cells, includ-
ing cardiac and skeletal muscle cells, neurons, endocrine and
sensory cells, thereby controlling numerous physiological pro-
cesses. Ten genes named CACNA1A-S encode the pore-channel
Cav subunits that generate the L-types (Cav1), the neuronal P/Q-
, N-, and R-types (Cav2), and the T-type (Cav3). Cav1 and
Cav2 subunits are high voltage-activated channels, which also
include regulatory subunits β, α2δ, and γ. Among calcium chan-
nels, L-type Cav1.2 channel is widely distributed in the brain
in the somatodendritic area of neurons, in cardiac myocytes,
Table 2 | Genetic tests for some neuropsychiatric disorders associated
to ion channels dysfunctions (http://www.orpha.net).
Disease Gene (protein) Chromosome
Timothy syndrome CACNAJC (Cav1.2) 12p13.3
SeSAME syndrome KCNJ10 (Kir4.1) 1q23.2
Birk Barel mental retardation
dysmorphism syndrome
KCNK9 (TASK3) 8q24.3
Dravet syndrome and epileptic
encephalopathy early infantile
SCN1A (Nav1.1) 2q24.3
Epileptic encephalopathy, early
infantile type
SCN2A (Nav1.2) 2q24.3
Epileptic encephalopathy, early
infantile type 13
SCN8A (Nav1.8) 12q13.13
Epileptic encephalopathy, early
infantile type 7
KCNQ2 (KTQ2) 20q13.33
lymphocytes, pancreatic β-cells. Interestingly, there is increasing
information for an association of Cav1.2with psychiatric disorders
(Ferreira et al., 2008; Sklar et al., 2008).
VOLTAGE-GATED SODIUM CHANNELS
Voltage-gated sodium channels (Nav channels) are essential for
generation and propagation of signals in electrically excitable tis-
sues. Three sodium channel genes encoding distinct α-subunit
isoforms SCN1A, SCN2A, SCN3A are highly expressed in neu-
rons and glia throughout the central nervous system (CNS) and
peripheral nervous system. Mutations in genes encoding Nav
channels are signiﬁcant factors in the etiology of neurological
diseases and psychiatric disorders, including various types of idio-
pathic epilepsy, ataxia, and sensitivity to pain. The SCN1A,SCN2A,
SCN3A, SCN7A, and SCN9A genes form a 1.4-Mb SCN cluster on
chromosome 2q24.3 (Catterall, 2012).
POTASSIUM CHANNELS
Potassium channels set the resting membrane potential, repolar-
ize neurons following action potentials, and also mediate some
forms of subthreshold signaling. K+ channels are classiﬁed on the
basis of the primary amino acid sequence of the pore-containing
α-subunit into three major families: (1) voltage-gated K+ chan-
nels (Kv) containing six or seven transmembrane regions with a
single pore, including also KCNQ, human ether-a-go-go-related
gene (hERG), eag, and Ca2+-activated K+ channels; (2) inward
rectiﬁers (Kir) containing only two transmembrane regions and a
single pore; and (3) two-pore tandemK+ channels containing four
transmembrane segments with two pores (Maljevic and Lerche,
2012). Among neuronal Kv channels, the low voltage-activated
Kv1.1 and Kv1.2 are expressed mainly in the cerebellum, hip-
pocampus, and thalamus. These channels, located in the axons
of neurons, do not affect the ﬁrst action potential but increase
the action potential threshold and guarantee the correct propaga-
tion of electrical signals (Jan and Jan, 2012). Kv1.1 co-assembles
with Kv1.4 at the hippocampal mossy ﬁber boutons, where they
mediate neuronal activity-dependent processes involved in synap-
tic plasticity (Imbrici et al., 2007). The KCNQ2–5 channels are
expressed in different combinations in neurons. They mediate the
M-currents inhibited by acetylcholine (ACh) through the mus-
carinic receptors involved in the ACh-dependent postsynaptic
depolarization. M-current plays a critical role in thalamic sen-
sory pathways in attention, perception, and memory. It remains
one of the most promising ion channel disease candidate gene
and it maps to a locus on chromosome 6q14, a region repeatedly
suggested containing an attention-deﬁcit/hyperactivity disorder
(ADHD) locus, a schizophrenia locus, and bipolar disease suscep-
tibility alleles (Gargus, 2006). HERG channels form a particular
subfamily of voltage-gated potassium channels known as H or
Kv11. HERG1 (also referred as KCNH2 or Kv11.1) plays an impor-
tant role in the repolarization of the cellular membrane potential
of excitable cells, as cardiac, neuronal, and smooth muscle cells
(Maljevic and Lerche, 2012).
Since the cloning of the ﬁrst inward rectiﬁers, new mem-
bers of this family have been identiﬁed, including the Kir4.1–2
(KCNJ10,15), Kir5.1 (KCNJ16), the G protein-coupled (GIRK)
Kir3.1–4 (KCNJ6,5,9,3), and the ATP-sensitive (KATP) Kir6.1–2
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(KCNJ8,11). These channels play pivotal roles in many organs
including brain, ear, and retina. Kir4.1 subunit is widely expressed
in kidney and brain where it can form homotetrameric channel or
heterotetramers with Kir5.1 (KCNJ16), with distinct physiologi-
cal properties (Hibino et al., 2010). GIRKs are widely distributed
in the brain and play an important role in regulating neural
excitability through the activation of various G protein-coupled
receptors (Hibino et al., 2010). ATP-sensitive K+ (KATP) channels
are octameric complexes of the pore-forming Kir6.1–2 sub-
units and of regulatory sulfonylurea receptor (SUR) subunits
belonging to ATP-binding cassette protein superfamily. KATP
channels couple metabolism to the electrical activity of the cells.
Indeed, several studies have shown that they can be associated
with glycolytic proteins including pumps and enzymes such as
pyruvate kinase (PK), to form macromolecular complexes that
contribute to channels regulation (Dhar-Chowdhury et al., 2005;
Mele et al., 2012).
NEUROPSYCHIATRIC DISORDERS ASSOCIATED TO ION
CHANNELS DYSFUNCTIONS
BIPOLAR DISORDER
Bipolar disorder is a common, chronic and recurring medical
disorder characterized by episodes of mania, that is extremely ele-
vated mood, increase in motor activity, racing thought patterns,
impaired judgment, decreased sleep and sometime psychosis, and
depression (Offord, 2012). The prevalence of the disease is around
1% of the population, though, due to the problem of misdiag-
nosis, the prevalence may be higher (Offord, 2012). Increasing
evidence suggests that BPD stems from structural and functional
impairments in various brain regions, mainly in corticolimbic
structures linked with disrupted emotional and executive func-
tioning (Cousins and Grunze, 2012; Price and Drevets, 2012). In
addition, mood disorders, particularly BPD, are associated with a
disruption inmechanisms and factors that govern cell survival and
neural plasticity (Rogawski and Loscher, 2004). Several research
groups have performed independent GWAS of BPD supporting
the view that ion channels dysfunctions may also contribute to the
genetic etiology of this disease.
Calcium channels involvement
The strong association of calcium channels to BPD came out
from the analysis of published GWAS data, concluding that the
Cav1.2 gene (CACNA1C) is the most relevant susceptibility locus
associated with BPD. Indeed, distinct studies, including the Well-
come Trust Case Control Consortium, STEP-UCL, STEP-BD,
and ED-DUB-STEP2, identiﬁed one single-nucleotide polymor-
phism (SNP), rs1006737, located in the third intron of the Cav1.2
gene (Ferreira et al., 2008; Sklar et al., 2008; Liao and Soong,
2010; Psychiatric GWAS Consortium Bipolar Disorder Working
Group, 2011). Furthermore, BPD was also associated with SNP
rs10994336 in ankyrin 3 gene (ANK3; Ferreira et al., 2008) which
encodes a family of proteins that was thought to be involved in the
assembly of Nav channels and proper functioning at the nodes of
Ranvier (Poliak and Peles, 2003). One related study by Curtis et al.
(2011) also identiﬁed a SNP, rs17645023, between the CACNG5
and CACNG4 genes in patients with BPD. These latter genes
code for two γ subunits of neuronal Cav channel. In addition,
Wilson et al. (2006) screened the postmortem brain DNA of 35
BPD cases and reported DNA copy number variations (CNV) in
several loci including GLuR7 (encoding a kainate receptor sub-
unit),AKAP5 (encoding amember of theAkinase anchor protein),
and CACNG2 (encoding a Cav channel γ subunit). In another
study, a total of 709 bipolar patients, 645 patients with schizophre-
nia, 189 patients with schizoaffective disorder, and 1,470 control
individuals were screened using the multiplex amplicon quan-
tiﬁcation method. A rare, partial deletion of 35.7 kb was found
in CACNA2D4 (encoding the Cav channel α2δ4 subunit), in two
unrelated late onset bipolar patients and in one control individual
(Van Den Bossche et al., 2012). The functional correlation of these
genetic variants to the pathogenesis of BPD is largely unknown;
some hypotheses can be made, though. First, CACNA1C and
ANK3 genes are involved in glutamatergic signaling which is inte-
gral to normal neuronal function (Wilson et al., 2006) and was
previously found to play a role in BPD etiology (Liao and Soong,
2010). Second, the most effective drug to treat BPD, lithium, was
reported to down-regulate both ANK3 and Cav1.2 channel in the
mouse brain (Lee et al., 2012). Third, the gamma subunits sta-
bilize the calcium channel in an inactivated state and regulate
the trafﬁcking and gating properties of AMPA-selective glutamate
receptors. Finally, the α2δ4 subunit encoded by CACNA2D4 asso-
ciates with the Cav1.2 α subunit and doubles calcium inﬂux. The
CACNA1C gene is also localized in proximity of the CACNA2D4
gene on chromosome 12, as both genes are only 135 kb apart.
An attempt to give functional relevance to genetic data and
to shed light into neural mechanisms of genetic risk was pro-
posed by Bigos et al. (2010). They used functional MRI to ﬁnd a
correlation between the occurrence of CACNA1C SNPs and spe-
ciﬁc patterns of brain activity characteristic of patients affected
by mental illness (Bigos et al., 2010). Indeed, they found that
healthy individuals carrying the SNP rs1006737 showed increased
hippocampal activity in response to emotional stimuli, a pattern
that has been associated with the risk for BPD; the same indi-
viduals also showed increased prefrontal activity during working
memory tasks, a clinical feature typical of schizophrenia. More-
over, this study demonstrated that the molecular mechanism of
genetic risk appears to relate at least in part to regulation of gene
expression. Indeed, carriers of the risk SNP had increased lev-
els of CACNA1C mRNA in the human dorsolateral prefrontal
cortex measured from postmortem brain samples. Calcium chan-
nels are involved in various aspects of neuronal maturity during
development and throughout adulthood (Gargus, 2009; Liao and
Soong, 2010); therefore alterations in gene expression may also
affect the functional activity of brain circuitries implicated in both
mental conditions. This study also suggests that it may be worth
considering genotype or brain imaging based phenotypes as indi-
vidual predictors of response to psychiatric agents in clinical trials
(Liao and Soong, 2010).
Potassium channels involvement
Potassium channels have been proposed to play a role in mech-
anisms of neural plasticity which are altered in various psy-
chiatric disorders, especially in hippocampus (Askland, 2006;
Fontan-Lozano et al., 2011; Shah et al., 2011; Kristensen et al.,
2012). Multiple linkage and association studies have suggested
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chromosome 8q24 as a promising candidate region for BPD (Park
et al., 2004; Zandi et al., 2008). Zhang et al. (2010a) performed a
detailed association analysis on 2,756 SNP markers in the chromo-
some 8q24 region of 3,512 individuals from 737 families. Their
results showed suggestive evidence of association of BPD with
loci near KCNQ3 gene, encoding the voltage-gated potassium
channel Kv7.3. Kiselycznyk et al. (2012), instead, excluded the
involvement of Kir4.2 in anxiety or depression by analyzing the
neurological functions of KCNJ15 knock-out mice on a battery of
behaviors including those related to anxiety and depression, and
on plasticity-related learning tasks.
SCHIZOPHRENIA
Schizophrenia is a serious mental disorder affecting around 1%
of the general population worldwide (Askland et al., 2012; Mulle,
2012; Sullivan et al., 2012). Symptoms of schizophrenia include
dysfunction of executive functioning (symptoms of cognitive
disorganization), social responsiveness (negative symptoms, or
asociality), and sensory-perceptual integration (classical posi-
tive symptoms, including hallucinations and delusions; Askland
et al., 2012). Several lines of evidence increasingly suggest that
schizophrenia is a disorder of brain development and plasticity,
where the activity and excitability of hippocampus, substantia
nigra, ventral tegmental area, and prefrontal cortex are strongly
altered (Eichhammer et al., 2004; Oxley et al., 2004; O’Donnell,
2012; Silveira et al., 2012; Stachowiak et al., 2013). GABA and
glutamate neurotransmission emerged as critical elements in
schizophrenia pathophysiology (Coyle et al., 2012; Seshadri et al.,
2013), and one hypothesis proposes dysruption of cortical
interneurons as ﬁnal common pathway by which several different
etiological factors can yield the symptoms characteristic of this
disease (Nakazawa et al., 2012; O’Donnell, 2012). Genetic linkage
and association studies have recently begun to identify strong can-
didate risk genes for schizophrenia, including some ion channels
genes (Askland et al., 2012; Lee et al., 2012; Mulle, 2012; Owen,
2012; Vukadinovic and Rosenzweig, 2012).
Calcium channels involvement
Next to BPD, the rs1006737 SNP in CACNA1C was found to be a
susceptible SNP in schizophrenia in separate studies, though with
less statistical power compared to BPD, suggesting possible overlap
of genetic risk for both diseases (Moskvina et al., 2009; Green et al.,
2010; Sullivan et al., 2012).
Potassium channels involvement
Potassium channels are widely distributed in the CNS and thought
to have a role in modulating electrical excitability in neu-
rons, regulating action potential duration and neurotransmitters
release. Therefore, it is no surprise that some potassium chan-
nel genes have been considered candidate for susceptibility to
schizophrenia.
KCNN3, encoding the small conductance calcium-activated
potassium channel SK3, is located at 1q21, a region repro-
ducibly and strongly implicated in schizophrenia. Several lines
of neuroanatomical, physiological, and pharmacological evidence
suggested that a SK3 channels may constitute a pharmacological
target to improve cognition in schizophrenia and other condi-
tions with cognitive impairment (Gargus, 2006). In man, SK3
is expressed most abundantly in the ventral tegmental area,
in the substantia nigra, the subthalamic nuclei, hippocampus,
and amygdala (Dror et al., 1999). This distribution is consistent
with expression in the dopaminergic neurons that contribute
to the nigrostriatal and mesolimbic pathways, that are impli-
cated in schizophrenia. Moreover, this brain network abundantly
expresses the D2 dopamine receptor, the molecular target of typi-
cal and atypical antipsychotic drugs. SK channels are the major
determinant of the afterhyperpolarization phase (AHP) of the
action potential, which regulates the spontaneous frequency and
precision of mid-brain dopaminergic neurons. Pharmacological
blockadeof SKchannel enhances bursting activity of theseneurons
in rats in vivo and increases dopamine release. Thus, alterations in
the SK3 channels might signiﬁcantly affect monoaminergic neu-
ron excitability, producing excess dopamine release, a process long
implicated in schizophrenia (Gargus, 2006).
An association between the polymorphic CAG repeat length
in the N-terminal coding region of KCNN3 and schizophrenia
has also been questioned, but most results remain quite equiv-
ocal. Grube et al. (2011) recently showed that the CAG repeat
does not inﬂuence susceptibility to schizophrenia but modify
its phenotype. Using the Göttingen Research Association for
Schizophrenia (GRAS) data collection of patientswith schizophre-
nia, these authors performed a phenotype-based genetic associa-
tion study of KCNN3. They show that long CAG repeats reduce
SK3 channel function in HEK 293 cells and, in schizophrenic
samples, are speciﬁcally associated with enhanced cognitive per-
formance (Grube et al., 2011). However, interplay of multiple
causative factors, perhaps thousands of potential combinations
of genes/genetic markers, and an array of different environmen-
tal risks, might contribute to the development of a schizophrenic
phenotype.
Transgenic mice provided valuable tools to unravel the spe-
ciﬁc involvement of SK3 channels in synaptic plasticity. Indeed,
in the doxycycline-induced conditional SK3-deﬁcient mice some
aspects of working/short-term memory are disrupted. In addi-
tion, these cognitive deﬁcits in mice are paralleled by reduced
brain-derived neurotrophic factor (BDNF) mRNA expression, in
the dentate gyrus and CA3 area of the hippocampus, which is
also a marker of depression. Hence, the biological substrate for
the cognitive impairments in SK3 knock-out mice could conceiv-
ably entail reduced trophic support of the hippocampus (Jacobsen
et al., 2009).
The association of HERG1 gene with schizophrenia stems from
the observation that an adverse effect of antipsychotic agents is the
acquired long QT (LQT) syndrome, which results from the block-
ade of the HERG1 channel. Huffaker et al. (2009) studied two
family-based cohorts and three case–control cohorts of European
ancestry and reported HERG1 as a previously undescribed poten-
tial susceptibility gene for schizophrenia. The risk alleles predicted
increased expression of a brain-selective isoform, KCNH2–3.1 (or
Kv11.1–3.1; Huffaker et al., 2009). Atalar et al. (2010) genotyped
four SNPs in 7q36.1 region (two SNPs, rs1805123 and rs3800779,
located on HERG1, and two SNPs, rs885684 and rs956642, at the
3′-downstream intergenic region) and then performed SNP and
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haplotype association analyses in 84 patients with schizophrenia
and 74 healthy controls. Both genotype and allele frequencies
of rs3800779 were signiﬁcantly different between populations.
Moreover, two previously undescribed four-marker haplotypes
which are located in the chromosome 7 position encompassing
HERG1, were either over-represented or under-represented in
patients compared to controls (Atalar et al., 2010). Interestingly,
the functional characterization of the schizophrenia-associated
HERG1 isoform KCNH2–3.1 revealed altered gating kinetics and
lower current accumulation which will result in longer lasting
trains of action potentials. Increased expression of these channels
in the brain of schizophrenia patients might therefore contribute
to disorganize neuronal ﬁring (Heide et al., 2012). In addition,
the genetic variation associated with KCNH2–3.1 expression was
reported to inﬂuence the therapeutic effects of antipsychotic drugs
(Apud et al., 2012).
An animal model which lacks the KCNH3 channel has been
generated. It clariﬁed the critical involvement of this channel in
cognitive function. Indeed, KCNH3 knock-out mice displayed
enhanced performance in behavioral tasks related to working
memory, spatial reference memory, and attention compared to
their wild-type littermates (Miyake et al., 2009). In addition, these
mice had neither the seizures nor the motor dysfunction that
are often observed in other potassium channel-deﬁcient animals.
Conversely, the overexpression of KCNH3 in the forebrain caused
impaired performance in cognitive tasks. The results indicate that
KCNH3 represent a K+ channel that contributes preferentially and
bidirectionally to cognitive function (Miyake et al., 2009). Interest-
ingly, cognitive deﬁcits in schizophrenia have received increasing
attention, as they are a core feature of the disease and perhaps
the strongest predictor of outcome (O’Donnell, 2012). There-
fore, SK3 and KCNH3 knock-out mice may likely help unraveling
the contribution of dysfunction in executive functioning in the
etiopathology of schizophrenia.
Yamada et al. (2012) recently identiﬁed a SNP (rs3106653) in
the KCNJ3 gene as a result of a GWAS of schizophrenia in the
Japanese and Chinese population. KCNJ3, also termed GIRK1 or
Kir3.1, is a member of the G protein activated inwardly recti-
fying K+ channel group. The analysis of transcript levels in the
dorsolateral prefrontal cortex of postmortem brains from patients
with schizophrenia and BPD and from healthy controls, revealed
signiﬁcantly lower KCNJ3 expression in patients compared with
controls. These data suggest that this gene is genetically associated
with schizophrenia in Asian populations and a more compre-
hensive analysis extended to other populations will be required
(Yamada et al., 2012).
AUTISM SPECTRUM DISORDERS
Autism spectrum disorders are characterized by the concomitant
occurrence of impaired social interaction, restricted, persevera-
tive and stereotypical behavior, and abnormal communication
skills (Freitag et al., 2010; Devlin and Scherer, 2012). These dis-
orders affect about 1 in 110 individuals, with onset before the
age of 3 years (Devlin and Scherer, 2012). The etiology remains
largely unknown, in large part because most cases of ASD arise
from a mixture of multiple environmental and genetic inﬂuences,
making it difﬁcult to forge causal links to behavior (Freitag et al.,
2010; Carter and Scherer, 2013). Moreover, the extreme locus het-
erogeneity underlying ASD renders the identiﬁcation of causative
or risk associated genes quite difﬁcult, necessitating the analysis
of very large cohorts for validation (O’Roak et al., 2012; Sanders
et al., 2012; Carter and Scherer, 2013). Among the genes asso-
ciated with ASD, most are involved in synaptic plasticity and
synaptogenesis, such as neuroligin, neurexin, SHANK, methyl-
CpG-binding protein 2 (MeCP2), cyclin-dependent kinase-like 5
(CDKL5), and reelin genes (Freitag et al., 2010; Sullivan et al., 2012;
Carter and Scherer, 2013). Therefore, a developmental deregula-
tion of neuronal networks due to postnatal events, compromising
cell differentiation, synaptic formation, and plasticity has been
suggested to trigger and/or exacerbate autistic behavior in humans
(Sicca et al., 2011; Bender et al., 2012; Ebert and Greenberg, 2013).
In addition, none of these identiﬁed genetic variants are associ-
ated solely with ASD; they are rather also implicated in intellectual
disability, epilepsy, and other psychiatric conditions, suggesting
shared biologic pathways (Carter and Scherer, 2013). This is also
the case of some neuronal ion channels implicated in the patho-
genesis of autism in association with other clinical features (Sicca
et al., 2011; O’Roak et al., 2012; Sanders et al., 2012).
Here we focus on TS, a form of ASD associated with mutations
in a neuronal calcium channel, and Dravet syndrome (DS), which
is caused by mutations in neuronal sodium channels and presents
a typical epileptic phenotype of infancy; we also report clinical
cases with the epilepsy/autism phenotype in which mutations in
an inward rectiﬁer potassium channel have been found. Finally,
we included psychiatric disorders, caused by antibodies directed
against potassium channel complexes.
Calcium channels involvement
The CACNA1C gene, is the only gene known to be associated with
TS,which is therefore considered a monogenic neurodevelopmen-
tal disorder (Pas¸ca et al., 2011). This is a complex disorder that
affects multiple organs, characterized by autistic traits and also
LQT syndrome, webbed ﬁngers and toes, dysmorphic facial fea-
tures, and immunodeﬁciency (Gargus, 2009). It is a rare childhood
disease with less than 20 TS patients identiﬁed to date worldwide
and an average survival of 2–3 years, the major cause of death
being cardiac ventricular ﬁbrillation (Gargus, 2009; Bidaud and
Lory, 2011). In 2004, Splawski et al. (2004) described two muta-
tions, G406R and G402S in the alternative splice exon 8 of Cav1.2
linked to TS. This exon is expressed mainly in brain and heart. The
functional characterization of these mutations in heterologous
expression systems revealed a gain of channel function, signiﬁ-
cantly due to loss of voltage-dependent inactivation. This resulted
in heightened calcium inﬂux, which may be a contributing factor
to the multisystem defects in vivo (Liao and Soong, 2010). Indeed,
a sustained entry of calcium into the cardiac myocytes due to
impaired inactivation of Cav1.2 channels increases the duration
of the action potential, and explains the prolonged QT inter-
val (Bidaud and Lory, 2011). Interestingly, in brain, this channel
mediates a variety of neuronal calcium-dependent processes and
regulates calcium inﬂux related to dendritic cells (Gargus, 2006;
Catterall, 2011).
Important results about Cav1.2 channel function and abnor-
malities came from studies on genetically engineered animal
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models that showed that Cav1.2 channel plays important roles
in remote spatial memories and fear memory extinction (Bader
et al., 2011). The mouse model of TS bears the G406R mutation in
the CACNA1C gene (Bader et al., 2011). While homozygous and
heterozygous mice are not viable, heterozygous TS2 mice, that are
allowed to keep an inverted neomycin cassette, survive through
adulthood because the mutation-bearing channel is expressed at
lower level. These animals exhibit distinct traits strikingly remi-
niscent of the entire core triad of ASD: impaired social interaction,
impaired vocalization, and restricted and repetitive/perseverative
behavior (Bader et al., 2011). To date, no pre-clinical study has
been performed on these animals but it would be of interest to
determine whether the various reported behaviors can be mod-
iﬁed by L-type channel blockers, either by early intervention or
acute treatment.
A fascinating study on patients affected by TS has recently
been reported, which supports the hypothesis that ASD arise
from defects in connectivity between cortical areas (Geschwind
and Levitt, 2007) and suggests the contribution of increased cate-
cholamine synthesis in the pathophysiology of ASD. Indeed, Pas¸ca
et al. (2011) demonstrated that neurons from induced pluripo-
tent stem cells derived from individuals with TS have defects in
calcium signaling and activity-dependent gene expression. They
also show abnormalities in cell differentiation, including decreased
expression of genes that are expressed in lower cortical layers
and in callosal projection neurons. In addition, these neurons
show abnormal amount of tyrosine hydroxylase and increased
production of norepinephrine and dopamine. These ﬁndings pro-
vide strong evidence that Cav1.2 regulates the differentiation of
cortical neurons in humans and that gain of function TS muta-
tions could likely impact neuron development and/or excitabil-
ity, thus contributing to the presentation of the autistic traits
(Pas¸ca et al., 2011).
Besides TS, there is no clear evidence to date for a direct link
between CACNA1C and autism. However, GWAS suggest a pos-
sible role of SNPs within calcium channels genes in ASD (Liao
and Soong, 2010). One SNP, rs10848653, is located in CACNA1C,
two others, rs198538 and rs198545, in CACN1G, and a fourth,
rs5750860, located in CACNA1I, that encode T-type calcium
channels (Strom et al., 2010; Lu et al., 2012).
Sodium channels involvement
Various clinical studies assessed the involvement of Nav chan-
nels genes in psychiatric developmental diseases including ASD.
Early genome-wide scan studies for autism susceptibility genes
showed a potential susceptibility region on locus 2q (Philippe
et al., 1999; International Molecular Genetic Study of Autism
Consortium [IMGSAC], 2001; Weiss et al., 2003) that includes
SCN1A, SCN2A, and SCN3A genes. These results have been con-
ﬁrmed by other laboratories more recently. Indeed, Chen et al.
(2010) reported a 2.8-Mb de novo cryptic deletion on chromo-
some 2q24.2/q24.3 detected by array-CGH (comparative genomic
hybridization), involving nine genes including SCN2A and SCN3A
in a patient with autistic features, developmental delay, language
impairment, mental retardation, and dysmorphic features. These
ﬁndings suggested that deletion of SCN2A and SCN3A might be
responsible for the autistic features (Chen et al., 2010). Moreover, a
denovomissensemutation inSCN1A (P1894L),has been identiﬁed
byusing amolecular inversionprobe technology in 2,500 individu-
als, including 1,703ASD probands and 744 controls. The missense
variant is located at a highly conserved position in SCN1A and is
predicted to be functionally deleterious. The proband is severely
affected, with evidence of early onset, possible regression, lan-
guage delay, epilepsy, andmild intellectual disability (O’Roak et al.,
2011, 2012). In a similar study, Sanders et al. (2012) identiﬁed,
using whole-exome sequencing of 928 individuals, two probands
each carrying two independent non-sense variants disrupting the
SCN2A gene.
Interestingly, several case reports indicate that the SCN1A,
SCN2A, and SCN3A genes are usually associated to epilepsy
complicated by neurobehavioral comorbidities, which include
cognitive impairment, psychiatric disorders, and social prob-
lems. Indeed, Pescucci et al. (2003) reported a 10.4-Mb deletion
of 2q24.3eq31.1 spanning a cluster of sodium channel genes
including SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A in a
4-year-old girl with seizures, postnatal growth retardation, micro-
cephaly, facial dysmorphism, developmental delay, stereotypic and
repetitive hand movements, and sleep disturbances. Davidsson
et al. (2008) described large deletions involving the entire 1.4-Mb
sodium channel cluster on chromosome 2q24.3 in patients with
seizures, growth and mental retardation, dysmorphic features,
and microcephaly. An attempt of genotype–phenotype correla-
tion comes from Bartnik et al. (2011) who proposed that missense
mutations of SCN2A are responsible for isolated epilepsy, whereas
inactivating loss of function mutations or deletion CNVs caus-
ing haploinsufﬁciency of SCN2A, can be responsible for a more
severe phenotype presenting psychiatric abnormalities, in addi-
tion to epilepsy. By using a clinical exon-targeted array-CGH,
these authors have identiﬁed a de novo 112-kb deletion in chro-
mosome 2q24 including portions of the SCN2A and SCN3A genes
in a 25-year-old female with a history of infantile seizure, mental
retardation, anxiety disorders, and neurobehavioral and psychi-
atric abnormalities. The deletion removes exons 1–2 of SCN2A
and the non-coding exon 1a of SCN3A. Although only the non-
coding exon 1a of SCN3A was deleted in this patient, it cannot be
excluded that the function of SCN3A is also disrupted because of
thedeletionof thepromoter or transcriptionbinding sites (Bartnik
et al., 2011).
One of the most relevant examples of comorbidity of epilepsy
and psychiatric disorders linked to sodium channel dysfunction is
DS. DS, also termed severe myoclonic epilepsy in infancy (SMEI),
is a childhood epilepsy disorder associated with devastating effects
on cognitive and behavioral development, persisting in adulthood
(Bender et al., 2012). While early-life seizures are perhaps the most
striking feature of DS, psychomotor, visuospatial, and language
development are also impaired, and social development is severely
affected, with patients displaying recalcitrance, mood instability,
affective indifference, or autistic behaviors. Intellectual disability is
reported in the majority of cases (Bender et al., 2012). Mutations,
deletion, and duplication CNVs of SCN1A, ranging in size from a
single exon to extending beyond SCN1A, have been described in
patients with DS. Approximately 80% of patients with DS carry
loss of function mutations in SCN1A (Catterall et al., 2010; Escayg
and Goldin, 2010).
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Given that Nav channels are critical for action potential gener-
ation and propagation in neurons, it is predictable that mutations
in sodium channel might be detrimental to the normal function-
ing of the nervous system. Whereas it is easier to ﬁnd a causative
association between sodium channels dysfunctions and epileptic
attacks, the neural mechanisms responsible for autism spectrum
phenotypes, DS and other abnormal neurodevelopmental traits,
are less straightforward. In this regard, studies on animal models
have helped research in the ﬁeld by providing important insight
into the cellular and neural network mechanisms by which SCN1A
mutations may cause neural defects (Yu et al., 2006; Han et al.,
2012; Ito et al., 2013).
One major result obtained from in vitro studies is the contribu-
tion of GABAergic interneurons network to the pathophysiology
of DS. Indeed, SCN1A has been reported mainly in these GABAer-
gic fast-spiking cells in the neocortex and hippocampus, clustered
in the proximal portion of the axon initial segment, precisely
a region that is critical for the initiation and generation of
action potentials (Lorincz and Nusser, 2008). Consistently with
Nav1.1 expression, it has been shown that loss of function
SCN1A mutations associated to epileptic disorders cause func-
tional impairments in GABAergic interneurons, reducing GABA
release and leading to a loss of appropriate inhibition in related
neuronal networks (Bender et al., 2012). This will create an imbal-
ance between excitation and inhibition in the brain, generating
seizures (Catterall et al., 2010). In addition to epilepsy, impair-
ments in GABAergic interneurons may also likely contribute to
the cognitive symptoms observed in patients (Bender et al., 2012).
Actually, these fast-spiking cells are critical for the synchronization
and spatiotemporal patterning of neural activity which is essen-
tial for the strengthening of cognitive processes (Fuchs et al., 2007;
Murray et al., 2011). These observations have been conﬁrmed in
a conditional Scn1a+/− mouse with speciﬁc Nav1.1 reduction in
GABAergic forebrain interneurons. This mouse represents a clear
example of comorbidity of epilepsy and autism. It develops seizure
and multiple ASD behavioral phenotypes including hyperactivity,
stereotyped behaviors, social interaction deﬁcits, and impaired
context-dependent spatial memory. Importantly, these psychiatric
symptoms resulted a consequence of impaired GABAergic neuro-
transmission and not of neuronal damage from recurrent seizures
(Han et al., 2012), as traditionally believed (Hermann et al., 2008).
Indeed, there is a growing body of evidence that other factors are
involved in the occurrence of epilepsy comorbidities (Hermann
et al., 2008). In agreement with decreased GABAergic tone, treat-
ment of conditional Scn1a+/− mouse with low-dose clonazepam,
a positive allosteric modulator of GABAA receptors, completely
rescued the abnormal social behaviors and deﬁcits in fear mem-
ory in this mouse model of DS (Han et al., 2012). These results
indicate that low-dose benzodiazepine treatment could be a poten-
tial pharmacological intervention for cognitive deﬁcit and autistic
symptoms in DS patients.
In vitro studies also helped to clarify the cellular and physi-
ological changes in the brain during development, which is of
particular relevance to understand the role of SCN1Amutations in
ASD. Indeed, the developmental origin of several neuropsychiatric
disorders is now generally accepted (Bender et al., 2012; Piper
et al., 2012). It is noteworthy that early postnatal development
in rodents is highly dependent on changes in Nav brain expres-
sion. Nav1.1 expression increases during development reaching
a peak during the ﬁrst 4 weeks of life, while Nav1.2 and Nav1.3
amounts decrease during the second week of life (Beckh et al.,
1989). Consistently, in humans, Nav1.1 expression in the hip-
pocampus and cortex increases during early development, peaking
around 7–9 months of age (Wang et al., 2011). In mice, the Nav1.1
increase parallels both the neurophysiologic growth of fast-spiking
interneurons and the development of spatial cognition. Together,
the timing of the above developmental changes makes this period
especially susceptible to functional deﬁcits affecting neural net-
work activity. Indeed, during this period, mice with complete or
partial Scn1a deletion show reduced survival, increased propen-
sity to spontaneous or hyperthermia-induced seizures and slowed
cognitive development (Yu et al., 2006; Oakley et al., 2009; Ben-
der et al., 2012; Ito et al., 2013). Moreover, the observation that
interneurons of Scn1a knock-out mice fail to develop a narrow
action potential width characteristic of mature cells, suggests that
Scn1a expression is important for the conversion from slow to
fast-spiking cells (Yu et al., 2006). Therefore, although the effects
of SCN1A mutations on brain ﬁring and information processing
have not yet been directly tested, a consistent hypothesis is that
the deﬁcit in interneurons functioning during development may
consistently recapitulate autistic behaviors and cognitive decline
in addition to epileptic seizures.
Potassium channels involvement
There are also case reports of involvement of various types of
potassium channels in ASD. A case study reported a decrease in
Ca2+-activated K+ channel (BKCa) activity due to a disruption
of the BKCa gene (KCNMA1) in one subject with ASD (Lau-
monnier et al., 2006). A recent linkage analysis study on a large
Finnish pedigree proposed KCNJ10, coding for the Kir4.1 potas-
sium channel, as a candidate gene for ASD (Kilpinen et al., 2009).
Recently, Sicca et al. (2011) described two heterozygous KCNJ10
mutations (R18Q and V84M) in three children from two unre-
lated families with ASD, seizures, and intellectual disability. This
study indicated that the molecular mechanism contributing to
the disorder relates to an increase in either surface-expression
or conductance of the Kir4.1 channel expressed in a heterolo-
gous expression system (Sicca et al., 2011; Figure 1). In the brain,
Kir4.1 channels are expressed primarily in oligodendrocytes and
in astrocytes surrounding synapses and blood vessels, mainly in
the cortex, thalamus, hippocampus, and brainstem (Hibino et al.,
2010). Here, these channels control the resting membrane poten-
tial of astrocytes and are believed to maintain the extracellular
ionic and osmotic environment by promoting K+ transport from
regions of high [K+]o, which results from synaptic excitation, to
those of low [K+]o. This polarized transport of K+ in astrocytes,
referred to as“spatial buffering of K+,” is essential for normal neu-
ronal activity, excitability, and synaptic functions (Chever et al.,
2010). Dysfunction in the astrocytic-dependent K+ buffering has
been suggested as a common mechanism contributing to seizures
as well as to ASD behavioral traits, by altering neuronal excitabil-
ity and synaptic function, and may represent a new target for
therapeutic approaches (Sicca et al., 2011). Fifty to seventy percent
of autistic children show some degree of intellectual disability
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FIGURE 1 | (A) Kir4.1 channels localize on brain astrocytes both at
perisynaptic and at perivascular processes and control spatial K+ buffering.
(B) Upper panel : Pedigrees of two families harboring novel mutations in
KCNJ10 associated to autism/epilepsy phenotype. Squares are males and
circles females; solid black symbols represent affected children; slashes
denote deceased individual. Lower panel : Schematic representation of the
human Kir4.1 subunit with the two variants, R18Q and V84M. (B) Sample
current families recorded from Xenopus oocytes expressing equal amounts
of Kir4.1WT (C), R18Q (D), or V84M (E) mRNA. Notice that mutant channels
show increased current amplitudes compared to wild-type. Horizontal dashed
lines indicate 0 current level. The pulse protocol is shown as inset in (C). From
Sicca et al. (2011).
(Matson and Shoemaker, 2009). Both cognitive and autistic fea-
tures could be tied to postnatal developmental brain injury (Hong
et al., 2005) andKir4.1 channel activity shows a profound develop-
mental regulation, which correlates with both cell differentiation
and the developmental regulation of extracellular K+ dynamics
(MacFarlane and Sontheimer, 2000; Neusch et al., 2001). There-
fore, early abnormal functioning of mutant Kir4.1 channels may
impact the correct brain development, contributing to intellectual
and psychiatric signs. Moreover, astrocyte-released neuroactive
substances govern several functions including neuronal excitabil-
ity, excitatory and inhibitory synaptic transmission, and plasticity
(Yang et al., 2003; Zhang et al., 2003; Pascual et al., 2005) as well as
synaptogenesis and neuronal wiring (Collazos-Castro and Nieto-
Sampedro, 2001; Ullian et al., 2004) which will be compromised
by Kir4.1 mutations (Sicca et al., 2011). Therefore, even though a
direct causative link has still to be ascertained, different hypotheses
related to potassium homeostasis, cell differentiation, and synap-
tic plasticity have been evoked to correlate Kir4.1 mutations to
epilepsy and ASD. Several lines of evidence from animal models
of ASD come in support of the clinical studies. Interestingly, an
up-regulation of Kir4.1 has been found in locus coeruleus neu-
rons of an animal model of Rett syndrome, the MECP2-null mice
(Zhang et al., 2010b). Here, Kir4.1 overexpression might impair
noradrenergic modulation, leading to the autistic behaviors seen
in Rett syndrome (Zhang et al., 2010b).
Interestingly, another disorder with molecular and clinical
features different from the above described cases, has been asso-
ciated to Kir4.1 mutations. Indeed, independent clinical studies
unraveled the involvement of Kir4.1 in EAST/SeSAME syndrome,
that presents with a unique set of symptoms including epilepsy,
ataxia, mental retardation, hearing loss, and electrolyte imbal-
ance related to renal salt loss (Bockenhauer et al., 2009; Scholl
et al., 2009; Williams et al., 2010). Genetic screening revealed
that EAST/SeSAME patients are homozygous or compound het-
erozygous for novel missense mutations in KCNJ10 or present a
deletion of the C-terminal half of the protein Kir4.1 (Williams
et al., 2010). These studies showed that each of these muta-
tions compromises the function of both homomeric Kir4.1 and
heteromeric Kir4.1/Kir5.1 channels and that Kir4.1 function is
always reduced by distinct mechanisms (Sala-Rabanal et al., 2010).
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Furthermore, almost all mutations do not largely impair the abil-
ity of these channels to be expressed at the plasma membrane
indicating the potential utility of Kir channel openers for SeSAME
syndrome therapy (Tang et al., 2010). The localization and physi-
ological role of Kir4.1 channels in renal tubules and in the inner
hear (Hibino et al., 2010) well explain why loss of channel func-
tion causes sensorineural deafness and the electrolyte imbalance
reported for EAST/SeSAME patients. Less trivial would be to
ascertain the link between Kir4.1 reduction and both seizure sus-
ceptibility and cognitive dysfunctions. These clinical features, as
discussed before, might be at least in part attributed to chan-
nel expression and function in neurons and astrocytes during
development. Relevant clues can be drawn from Kir4.1 knock-
out mice, which display seizure, hearing loss, altered K+ transport
in hippocampus, impaired glutamate uptake by astrocytes, motor
impairment due to hypomyelination, but not clear signs of cog-
nitive decline as in affected patients bearing Kir4.1 mutations
(Djukic et al., 2007).
Other potassium channels have been implicated in develop-
mental disorders. BirkBarelmental retardationdysmorphism syn-
drome is a maternally transmitted genomic-imprinting syndrome
of mental retardation, hypotonia, and unique dysmorphism
with elongated face (Barel et al., 2008). The disease was mapped
on chromosome 8q24 and was caused by a missense mutation
(G236R) in the maternal copy of KCNK9 which encodes K2P9.1,
a member of the two pore-domain potassium channel (K2P)
subfamily (Kim et al., 2000). The mutant subunits gave rise to
non-functional homodimeric channels and showed a dominant-
negative effect when co-expressed with wild-type or with K2P3.1
(Barel et al., 2008). K2P potassium channels carry leak or back-
ground currents that are mostly time- and voltage independent.
These leak currents shape the duration, frequency, and amplitude
of action potentials, regulate cell excitability by modulating mem-
brane resting potential, and aremainly expressed in the cerebellum
(Kim et al., 2000; Goldstein et al., 2001; Kang et al., 2004). Due to
its localization and function it is reasonable that the K2P9.1 loss
of function during brain development might speciﬁcally disrupt
the efﬁciency of the cerebro-cerebellar pathways, resulting in cog-
nitive deﬁcits and deterioration in muscle strength and function
(Barel et al., 2008).
Autoimmune psychiatric disorders
A group of neuropsychiatric disorders affecting both adults
and children is caused by auto antibodies targeting macro-
molecular complexes containing a potassium channel (Irani
and Vincent, 2011; Kayser and Dalmau, 2011). The antibodies
are directed against the Kv1 voltage-gated potassium channels
(VGKC) and associated proteins including leucine-rich glioma-
inactivated 1 protein (LGi1) and contactin-associated protein 2
(Caspr2). Therefore, they are better termed “VGKC complex”
antibodies (Kayser and Dalmau, 2011; Lin et al., 2012). The
psychiatric symptoms present in patients with VGKC autoim-
munity include panic attacks, obsessive–compulsive behaviors,
and cognitive alterations (Irani and Vincent, 2011; Somers et al.,
2011).
Limbic encephalitis, a prototypic autoimmune neuropsychi-
atric disorder, is recognized by neurologists and psychiatrists by
its subacute onset and rapid progression of cognitive, mood, and
behavioral symptoms (Kitten et al., 2011; Somers et al., 2011).
Classically, symptoms evolve over days to weeks and include
psychiatric manifestations as diverse as irritability, depression,
hallucinations, and personality disturbances, with neurocognitive
changes in the form of short-term memory loss, sleep distur-
bances, and seizures (Kayser and Dalmau, 2011). Somers et al.
(2011) described the neuropsychiatric spectrum of Kv chan-
nel complex autoimmunity among 67 seropositive patients and
found a signiﬁcant correlation between severe neuropsychiatric
presentations (such as confusion, memory impairment, personal-
ity change, depression, anxiety, visual hallucinations, delusions,
and sleep disorders) and higher autoantibody values. Of 15
who received immunotherapy, 67% improved. Improvements
were most evident in patients treated early, which empha-
sizes the need for early diagnosis and immunotherapy initiation
(Somers et al., 2011).
Some cases of fever-induced refractory epileptic encephalopa-
thy in school-age children (FIRES) may have an immunological
basis (Haberlandt et al., 2011; Suleiman et al., 2011). This is a
clinically recognized epileptic encephalopathy of unknown eti-
ology in which onset of epilepsy is accompanied by a dramatic
cognitive decline, behavioral difﬁculties, and, in some cases,
the evolution of neurological signs. Illingworth et al. (2011)
described a case of FIRES in a 4-year-old boy with signiﬁ-
cant attention, memory, and word-ﬁnding difﬁculties, which
was associated with elevated Kv channel complex antibodies and
a signiﬁcant clinical and immunological response to immuno-
modulation.
Studies from genetically modiﬁed mouse models (Smart et al.,
1998) and from disease causing mutations in heterologous
expression systems (D’Adamo et al., 1999; Imbrici et al., 2011)
contributed to unravel the functional role of Kv1 channels in
the brain and the consequences of an altered activity on the
brain areas where they are expressed. Loss of function muta-
tions in Kv1.1 channels cause attacks of motor incoordination
due to altered GABAergic neurotransmission at the cerebellar
basket cell–Purkinje cell synapse (D’Adamo et al., 1999). Some
individuals bearing Kv1.1 mutations also experience epilepsy
and cognitive decline which may result from altered glutamate
neurotransmission at the hippocampal CA3 region, as a conse-
quence of impairedKv1.4–1.1/Kvβ1.1 channel inactivation (Geiger
and Jonas, 2000; Imbrici et al., 2006). Consistently, puriﬁed
immunoglobulin G from one individual with limbic encephali-
tis reduced VGKC function at mossy ﬁber-CA3 pyramidal cell
synapses and increased cell excitability. Moreover, α-dendrotoxin,
a selective Kv1.1, 1.2, and 1.6 subunit antagonist of VGKC,
mimicked the limbic encephalitis immunoglobulin G-mediated
effects (Lalic et al., 2011). These studies support the role of
Kv1.1 channels in brain disorders and the contribution of hip-
pocampus impairment to the genesis of epilepsy and cognitive
defects.
Among the autoimmune neuropsychiatric disorders involving
potassium channels, the Pediatric Autoimmune Neuropsychi-
atricDisordersAssociatedwith Streptococcal Infection (PANDAS)
presents neuromuscular symptoms, relapsing–remitting tics, and
obsessive–compulsive signs, together with group A β-hemolytic
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streptococcal pharyngotonsillitis (Snider and Swedo, 2003; Squin-
tani et al., 2010). An abnormal production of auto antibodies
against PK has been recognized among the pathogenic factors
(Kansy et al., 2006). In order to clarify the mechanism of the dis-
ease, Mele et al. (2012) proposed that KATP/PK complex might
represent a novel pathogenic target in PANDAS. Indeed, patch
clampexperiments inneuronal cell lines andmuscle ﬁbers revealed
that KATP channels are functionally associated to the PK and
that the ATP produced by the PK likely inhibits KATP channel
conductance (Mele et al., 2012). Moreover, anti-PK antibodies
have the potential to alter membrane-associated glycolytic ATP
production and display a dual mode of action on neuronal
KATP channels, potentiating KATP currents in the short-term
and reducing KATP currents in the long-term incubation. This
promotes cell survival and neuronal death, respectively. These
results suggest that in affected patients KATP channel opening
or closing by anti-PK antibodies, may change the resting mem-
brane potential, the spike generation during action potentials and
alter the neuronal overall excitability. Consequently, the extra-
cellular levels of several neurotransmitters, including dopamine,
serotonin, glutamate, and GABA will likely be affected (Milton
and Lutz, 2005; Chan et al., 2007; Soundarapandian et al., 2007).
Such changes might be relevant in the cortico-striato-thalamo-
cortical circuits, which modulate movement, executive functions,
and emotional control and might contribute to the pathophys-
iology of the disease (tics and obsessive–compulsive symptoms;
Squintani et al., 2010).
ION CHANNELS AS PHARMACOLOGICAL TARGETS IN
NEUROPSYCHIATRIC DISORDERS
Given the pivotal role played by ion channels in psychiatric dis-
orders (Gargus, 2006, 2009; Liao and Soong, 2010; Sicca et al.,
2011; Askland et al., 2012; Mele et al., 2012; O’Roak et al., 2012)
and their speciﬁc function and localization in brain areas impli-
cated in mental illness (Hibino et al., 2010; Catterall, 2012; Jan
and Jan, 2012), many channel subtypes have emerged as crit-
ical targets for therapeutics. Moreover, commercially available
medications for psychiatric diseases result to bind neuronal ion
channels, thus suggesting that these proteins may be involved
in the therapeutic action of conventional drugs (Ohno et al.,
2007; Eijkelkamp et al., 2012; Perucca and Mula, 2013). Indeed,
it is noteworthy that activation or inhibition of different ion
channels can alter the extracellular levels of several neurotrans-
mitters, including dopamine, serotonin, glutamate, and GABA,
which are notoriously implicated in psychiatric disorders (Aldana
and Sitges, 2012; Mele et al., 2012). In addition, medications
used to treat mental disorders work differently for different peo-
ple, are marginally effective and present several side effects.
Examples are ﬁrst- and second-generation antipsychotic drugs
that improve positive symptoms, but are poorly active for neg-
ative symptoms and not at all effective for cognitive deﬁcits
(O’Donnell, 2012). Therefore, for the mentioned considerations,
novel molecules acting as selective ion channels blockers and
openers are under development. Drug design and development
are being greatly assisted by the recently identiﬁed crystal struc-
tures of several ion channels, from high-throughput screening
methods and, ﬁnally, from transgenic mice for ion channel genes
and pharmacologically induced animal models of psychiatric dis-
orders. Here we summarize the main pharmacological strategies
directed to block or activate calcium, sodium, and potassium
channels.
CALCIUM CHANNELS PHARMACOLOGY
These channels have become drug targets for a range of cardio-
vascular and neurological diseases. The clinical value of calcium
channel inhibitors in mental illness has been considered follow-
ing experimental results showing an increased expression of the
CACN1AC transcript and/or an increase in calcium channel activ-
ity in some psychiatric conditions. Moreover, inhibition of Cav
channels probably translates into a reduction in excitatory neu-
rotransmission, which may be ultimately responsible for positive
effects on mood and behavior. Despite their potential, calcium
channel blockers have been studied clinically, in psychiatric dis-
orders such as mood disorders and substance abuse/dependence,
yielding conﬂicting results. There have been small clinical trials in
the past suggesting beneﬁt of verapamil and other calcium channel
inhibitors for some patients affected by BPDs, but the data have
been inconsistent and limited. Interestingly, nicardipine, a dihy-
dropyridine calcium channel blocker, was found to enhance the
antidepressant action of electroconvulsive therapy in 26 patients
affected by major depression (Dubovsky et al., 2001). Neverthe-
less, to date, there is not deﬁnitive evidence of efﬁcacy of any
typical calcium channel antagonists for neuropsychiatric disorders
(Casamassima et al., 2010). Other strategies to reduce calcium cur-
rents have been explored. Recently, Pas¸ca et al. (2011) reported
the beneﬁcial effect of a treatment with roscovitine, a cyclin-
dependent kinase inhibitor and atypical L-type channel blocker,
on neurons from induced pluripotent stem cells derived from indi-
viduals with TS, resulting from gain of function Cav1.2 mutations.
Besides targeting the Cavα1 subunit, recent calcium channel mod-
ulators are directed toward the accessory α2δ subunit. As a recent
study showed, the α2δ ligand pregabalin administration prevented
the appearance of depression-like behaviors induced by chronic
restraint stress, and promoted hippocampal neurogenesis in adult
stressed mice. The α2δ1 subunit and the nuclear factor-κB signal-
ing pathway have been suggested to play a role in drug-mediated
proneurogenic effects. These pharmacological activities of α2δ
ligands may help to explain their therapeutic activity as supple-
mental therapy for major depression and depressive symptoms in
post-traumatic stress disorder and generalized anxiety disorders
(Valente et al., 2012).
POTASSIUM CHANNELS PHARMACOLOGY
Researchers at Wyeth disclosed compounds that disrupt interac-
tion between Kv1α and β subunits and thus prevent Kv1.1 N-type
inactivation. Kv1 channels in brain contribute to hyperpolarize
the neuron following depolarization. In the hippocampus Kv1.1 is
co-expressedwith Kvβ1 (and other β subunits), which converts the
non-inactivating Kv1.1 into a transient, fast inactivating current,
reducing its ability to hyperpolarize the cell and thus increasing
glutamate release and neuronal excitability. Despite the current
development status of this therapeutic strategy is unknown, these
molecules may be useful for reducing neuronal hyperexcitability
in diseases such as epilepsy and neuropathic pain but could also
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be adjuvant in diseases presenting with cognitive symptoms of
hippocampal origin (Lu et al., 2008).
Promising therapeutic interventions target SK channels due
to their wide distribution in the CNS and contribution to neu-
ronal excitability. SK channels activation has been proposed in
several disorders involving loss of synaptic plasticity, including
loss of memory and learning disabilities, where physiological neu-
rotransmission needs to be restored (Gargus, 2006). Modulation
of SK channels has been suggested as a novel protective strategy
in neurological disorders where neuronal cell death and neu-
roinﬂammatory processes are prominent, included schizophrenia
(Dolga and Culmsee, 2012). Genetic and physiological data sup-
port the role of SK channels in the neuropathology of this disease.
Among SK channels, the SK3 isoform, controls pacemaker fre-
quency and precision in dopaminergic neurons and seem to play
a role in dopamine release in mid-brain pathways. Therefore,
this physiological function of SK channels could be explored
and SK openers proposed as a novel pharmacological strategy in
addition to classic antipsychotic drugs. Interestingly, the role of
SK channels in controlling the pacemaking activity of neurons
has been exploited in episodic ataxia type 2, a neurological dis-
ease caused by loss of function mutations in P/Q type calcium
channels. Non-selective SK channels activation with 1-EBIO or
chlorzoxazone repaired the precision of Purkinje cell pacemak-
ing and ameliorated the cerebellar signs in a mouse model of
episodic ataxia. Indeed, a reduced activation of SK channels, due
to decreased calcium entry into Purkinje cells, has been shown
to contribute to the disease (Walter et al., 2006; Alviña and
Khodakhah, 2010).
KCNQ/Kv7 potassium channels, the molecular counterpart of
brain M-current, have also received considerable interest by phar-
maceutical market over the past decade. These channels limit
repetitive ﬁring and cause spike-frequency adaptation (Rogawski,
2000), modulate synaptic plasticity and are inhibited by ACh
through the muscarinic receptors. Early studies with M-current
inhibitors like linopirdine demonstrated improvements in learn-
ing and memory performance in animals (Fontana et al., 1994). A
recent study with XE991, a second-generation M-current blocker,
in healthy mice has shown that the improvement in cognitive
abilities may be achieved by altering basal hippocampal synap-
tic activity and by decreasing the levels of KCNQ/Kv7.3 protein,
a pivotal subunit for the M-current. Furthermore, XE991 can
revert both the cognitive impairment associatedwith acetylcholine
depletion, and the neurodegeneration induced by kainic acid
(Fontan-Lozano et al., 2011). Consequently, inhibition of the hip-
pocampal M-current has been proposed as a general strategy to
enhance cognitive performance in healthy and aging individu-
als, as well as in those with neurodegenerative diseases (Brioni
et al., 1993; Jentsch, 2000). However, clinical efﬁcacy studies inves-
tigating improvement of cognitive function have not yet been
reported.
At the same time, a number of pharmaceutical companies
are involved in the development of KCNQ channel activators
to treat neurological diseases. The ﬁrst agent proven to enhance
M-current activity was retigabine. When examined in vivo, reti-
gabine exhibited anticonvulsant activity in a broad range of
seizure models and was successful in a number of clinical trials
in humans. After retigabine, others Kv7.2/Kv7.3 activators such
as ICA-27243 and ICA-105665 have been developed as anticon-
vulsant. Several ﬁndings support the use of these compounds
also for the treatment of neuropsychiatric disorders. Kv7 chan-
nel activation strongly suppresses dopaminergic activity and it
is well known that altered function of the dopaminergic sys-
tem is associated with neuropsychiatric disorders (Hansen et al.,
2008; Cousins et al., 2009; Gonul et al., 2009). Moreover, both
selective and non-selective Kv7.2/7.3 activators exhibit efﬁcacy in
animal models of anxiety, mania, BPD, ADHD, and schizophre-
nia (Hansen et al., 2008). Indeed, pharmacological stimulation
of heteromeric Kv7.2/Kv7.3 channels showed promising results
in an amphetamine and chlordiazepoxide induced hyperactiv-
ity model of mania (Redrobe and Nielsen, 2009). In addition,
neuroimaging studies in bipolar patients with mania revealed
alterations inmetabolic activity in corticolimbic areas and demon-
strated that Kv7 channel activation with retigabine and ICA-27243
reduces baseline cerebral glucose metabolic activity (Kristensen
et al., 2012). These two Kv7 channel openers dose-dependently
increased GSK3β in the prefrontal cortex and hippocampus,
regions implicated in the emotional and cognitive aspects of men-
tal illness. The association of GSK3β with Kv7 channel function
is relevant, as GWAS have identiﬁed polymorphisms implicating
GSK3β signaling cascades in BPD (Baum et al., 2008). Moreover,
researchers at Lundbeck demonstrated, in a conditioned avoidance
response paradigm model of antipsychotic activity, that retigabine
could inhibit avoidance responses, an effect blocked by the Kv7
inhibitor XE-991184. Retigabine was also able to inhibit hyper-
locomotor responses in phencyclidine-sensitized animals, which
is often considered as a disease model for schizophrenia (Scotty
et al., 2009). Interestingly, retigabine has recently been approved
for adjunctive therapy in partial-onset seizures (French et al.,
2011), and because bipolar patients often experience therapeu-
tic beneﬁt from treatment with anticonvulsant drugs (Altamura
et al., 2011), this also implies that Kv7 channel openers may also
prove to have clinical utility in the treatment of BPDs. Therefore,
these experimental and pre-clinical data support the hypothesis
that positive modulation of Kv7 channel function restores sev-
eral key signaling pathways in psychosis similarly to standard
drugs, like lithium and valproate, and emphasizes the poten-
tial beneﬁt of Kv7 channel openers in the treatment of these
diseases.
Kv11.1 (HERG) plays a crucial role in cardiac repolarization,
especially in the later phases of the action potential due to its
unique kinetics. As it is a promiscuous channel and binds to
a structurally diverse set of small molecules, many drugs have
been removed from the market or terminated during clinical
development because of cardiac side effects. It is now common
practice to assess the HERG blocking liability of compounds
before they are taken to the clinic. In the last few years several
HERG activators were developed and were considered potential
therapeutics for antiarrhythmia (Wulff et al., 2009). As exam-
ple, the small compound NS1643 has been shown to activate
native and heterologously expressed Kv11.1, Kv11.2, and Kv11.3
channels (Bilet and Bauer, 2012; Bagal et al., 2013). Besides
its relevance in cardiac physiology, relative overexpression of a
primate-speciﬁc, brain isoform of Kv11.1 (KCNH2–3.1), which
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lacks an N-terminal domain crucial for slow deactivation and
therefore induces high-frequency, non-adaptive ﬁring patterns in
cultured cortical neurons, has recently been linked to an increased
risk of schizophrenia (Huffaker et al., 2009). The authors of this
study speculate that isoform-speciﬁc inhibitors might be useful
for the treatment of schizophrenia. Alternatively, selective Kv11.1
channel activators could compensate for the reduced expression
of the full-length isoform. The physiological role of the different
Kv11 channels in theCNS is still under investigation and at present,
it is unclear whether Kv11 channels are suited as pharmacologi-
cal target to inﬂuence neuronal excitability in vivo. Nevertheless,
drugs speciﬁcally affecting a given Kv11 subunit would probably
diminish the unwanted side effects either in the heart or in the
brain.
Kir4.1 channel plays a critical role in K+ homeostasis in the
human CNS and mutations in this channel type gives rise to
adverse phenotypes with loss and gain of function. No selective
Kir4 modulators have thus far been disclosed. However, investiga-
tors studying antidepressant drugmodulation of glial cell function
have demonstrated that many of these drugs inhibit Kir4 with rel-
atively low afﬁnity. Indeed, selective serotonin reuptake inhibitors
(SSRIs), ﬂuoxetine and escitalopram, and tricyclic antidepres-
sant, nortriptyline, are known to block inward rectiﬁer potassium
channels. Interestingly,Ohno et al. (2007) found that SSRIs prefer-
entially inhibit Kir4.1 channel rather than Kir1.1 and Kir2.1. The
common structure–activity relationship between channel fami-
lies suggests a common Kir channel antidepressant binding site.
Two amino acids, Thr128 and Glu158, on transmembrane domain
2 of Kir4.1 are critical for the drug inhibition of the current
by ﬂuoxetine and nortriptyline (Furutani et al., 2009). Intrigu-
ingly, some serotonin reuptake inhibitors, are used for the clinical
management of repetitive and challenging behaviors in children
with autism (Blenner et al., 2011) and an up-regulation of Kir4.1
channels has been recently associated to the presentation of autis-
tic traits in children (Sicca et al., 2011). This may suggest that
astroglial Kir currents might be involved in their pharmacologi-
cal action. At the same time, it is also formally possible that Kir4
channel activators may promote glial cell K+ uptake and thereby
exhibit some antiepileptic activity required in SESAME/EAST
syndrome.
Also GIRK channels are inhibited by tricyclic antidepres-
sants and this effect may contribute to some of the therapeutic
effects and to the adverse effects, especially seizures and atrial
arrhythmias in overdose, observed in clinical practice (Kobayashi
et al., 2004). Interestingly, neuronal GIRK channels are indirect
target of antipsychotic drugs, being one of the main effec-
tors of serotonergic and glutamatergic neuroreceptors activation
(Fribourg et al., 2011).
The drug discovery of novel antipsychotic drugs, has recently
also demonstrated the role of neuronal and astrocytic KATP chan-
nels as interesting therapeutic target, in addition to D2 and
5-HT2A neuroreceptors. Indeed, these channels are expressed
in the neural circuits that are implicated in the pathophysiol-
ogy of schizophrenia and are modulated by dopamine receptors
(Lin et al., 1993). Moreover, diazoxide, anATP-sensitive potassium
channel opener, has been tried in the clinic as an adjunctive treat-
ment with haloperidol. It potentiated the effects of haloperidol
on the positive and general psychopathological symptoms of
schizophrenia. A novel brain KATP channel opener, iptakalim,
has been proposed by Sun et al. (2010) as a novel antipsychotic
molecule. They showed that in association with clozapine in
rats, iptakalim reduced amphetamine- andphencyclidine-induced
hyperlocomotion, disrupted selectively conditioned avoidance
responding and increased c-Fos expression in the medial pre-
frontal cortex, nucleus accumbens, and lateral septal nucleus (Sun
et al., 2010). This supports a role of KATP in the treatment of
schizophrenia.
Activators of K2P channels are anticipated to have a therapeu-
tic potential to treat neurological and cardiac diseases. Currently,
there are relatively few compound classes that have been shown to
selectively modulate the different subsets of this class of potassium
channels (Bagal et al., 2013).
SODIUM CHANNELS PHARMACOLOGY
A variety of approved drugs are modulators of neuronal sodium
channels for the treatment of clinical conditions associated with
abnormal cell excitability, mainly neuropathic pain and epilepsy
(Mantegazza et al., 2010). Some non-selective sodium channel
blockers, besides acting as antiepileptic drugs, can also be mood
stabilizers and antidepressants. Lamotrigine, a known sodium
channel blocker, has been shown to prevent with great efﬁcacy
episodes of depression, through a positive effect on corticolim-
bic network which is disrupted in BPD. In healthy volunteers, this
drug has shown a speciﬁc facilitatory effect on the prefrontal cortex
while, in vitro, it enhanced the power of gamma frequency network
oscillations induced by kainic acid in the rat hippocampus (Large
et al., 2009). Lamotrigine has indirect antiglutamatergic effects
by acting at Nav channels to stabilize neuronal membranes and
glutamate release. Interestingly, this drug is also effective for the
treatment of Lennox–Gastaut syndrome, a rare and intractable
form of childhood epilepsy associated with learning difﬁculties.
Phenytoin is an established antiepileptic drug with a robust capac-
ity to bind to and prolong the inactivation of mammalian, Nav
channels. Small randomized studies suggest that phenytoin may
be useful in the treatment of BPD (acute therapy for manic
episodes and maintenance treatment), major depressive disorder,
and impulsive aggression (Perucca and Mula, 2013). A prototypi-
cal sodium channel-blocking antiepileptic drug, carbamazepine is
approved by the Food and Drug Administration for the treatment
of acute manic and mixed episodes of BPD. This drug appears
to be effective for maintenance treatment of BPD, although to a
lesser extent compared with lithium; it may also be effective in
unipolar depression, whereas its utility in schizophrenia is still
uncertain (Perucca and Mula, 2013). These effects, however, can-
not be explained solely on the basis of the known sodium channel
block of each anticonvulsant, and other mechanisms or targets
are likely to be implicated. Indeed, lamotrigine also acts on other
molecular targets, such as the hyperpolarization-gated cationic
current in dendrites of pyramidal neurons, N- and P-type Cav
channels in cortical neurons and neocortical potassium currents
(Eijkelkamp et al., 2012).
Interestingly, typical antidepressant drugs have gained atten-
tion for their ability to block sodium channel. Importantly,
among the pathophysiological mechanisms of mood disorders,
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evidence that sodium homeostasis is altered also exists. Early stud-
ies found that erythrocyte and whole body intracellular sodium
concentrations are increased in patients with depression and BPD.
Furthermore, several effective mood-stabilizing and antidepres-
sant treatments reduce intracellular sodium concentrations or
inhibit, through blockade of Nav channels, sodium inﬂux (El-
Mallakh and Huff, 2001). In a mouse model of seizure, the
SSRI ﬂuoxetine was shown to behave as an anticonvulsant in a
dose- and time-dependent manner, and this action was accom-
panied by strong inhibition of persistent sodium current and
impairment of repetitive ﬁring. These ﬁndings suggest that the
effect of ﬂuoxetine on active membrane properties is similar
to that of many antiepileptic drugs, and this action may con-
tribute to anticonvulsant effects (Igelström and Heyward, 2012).
In an elegant study, Aldana and Sitges (2012) demonstrate that
besides the inhibition of 5-HT reuptake, sertraline is an effective
inhibitor of pre-synaptic sodium channels controlling neuro-
transmitter release. Of note, blockade of Nav channels also
results in inhibition of glutamate release (Farber et al., 2002),
which is itself associated with positive effects on mood and
behavior.
So far sodium channel openers have been considered only as
toxic compounds. However, a selective opener could have clini-
cal applications in some disorders. For example, a Nav channel
opener selective for Nav1.1, whose loss of function can cause
DS and other genetic epileptic syndromes, might be a particu-
larly effective antiepileptic drug for these syndromes. Similarly,
compounds able to selectively increase Nav1.1 expression levels
would probably be even more efﬁcacious in these cases, but little
has been done to develop drugs with this mechanism of action
(Bagal et al., 2013).
CONCLUSION
Voltage-gated ion channels, as the main determinants of intrin-
sic neuronal excitability, are implicated in many inherited and
acquired diseases and thus, they are particularly appealing targets
for pharmacological intervention. The reported research studies
suggest that ion channels genetic variants are potential mecha-
nisms of risk or causative factors for BPD, schizophrenia, and
ASDs (Gargus, 2009; Liao and Soong, 2010; Mele et al., 2012;
Somers et al., 2011; Askland et al., 2012; O’Roak et al., 2012).
The wide distribution of ion channels in brain and speciﬁ-
cally, their localization in hippocampus, prefrontal cortex, and
amygdala, brain areas which are disrupted in major psychi-
atric disorders, further support the association between these
proteins and mental illness (Gargus, 2006; Aldana and Sitges,
2012; Bender et al., 2012). Indeed, the calcium channel Cav1.2
has been strongly associated to the susceptibility to BPD and
schizophrenia (Liao and Soong, 2010), and several laboratories
report a link between schizophrenia and SK3 channels (Gargus,
2006). Mutations in Cav1.2 are the sole cause of TS (Bidaud and
Lory, 2011) and genetic variants in brain sodium channels are
responsible of several childhood neuropsychiatric disturbances
(Bender et al., 2012; Sanders et al., 2012). Kir4.1 is involved
in developmental syndromes with epilepsy, mental retardations,
deafness, and renal dysfunctions (Sala-Rabanal et al., 2010; Sicca
et al., 2011). Antibodies against Kv1.1 channels have been found
in patients with psychiatric symptoms (Illingworth et al., 2011;
Somers et al., 2011).
As commonly observed for other genetic diseases, neuropsy-
chiatric disorders and ASD in particular, present extreme genetic
heterogeneity, involving hundreds of genes, necessitating the
analysis of very large cohorts of patients and robust statistical
methodologies for validating results (Sanders et al., 2012). The
scenario is further complicated by the fact that de novo mutations,
may also contribute substantially to the genetic etiology of ASD
and schizophrenia (Mulle, 2012; O’Roak et al., 2012). Together
with the poor number of patients sometimes available for studies,
these factors make the genetic and clinical diagnosis often quite
difﬁcult.
As clear from the reports here summarized, in the majority of
clinical cases, ion channel variants are generally identiﬁed in indi-
viduals expressing neurologic or other syndromic features as well
as psychiatric features (e.g., epilepsy and psychiatric symptoms).
Epilepsy is very common among clinical ﬁndings, usually associ-
ated to autistic traits, major psychosis, and intellectual disability.
The overlapping etiopathology between epilepsy and psychiatric
illness has been discussed in the text for DS, where epilepsy occurs
together with autistic behaviors, but can be likely extended to
similar diseases, such as those caused by other ion and neuro-
transmitter operated channels (Derry et al., 2008; Liao et al., 2011;
Sicca et al., 2011). Relevant information about the etiopathology
of DS comes from studies on animal models which selectively
lack the Nav1.1 gene in cortical GABAergic interneurons (Han
et al., 2012). Animal studies have revealed that loss of Nav1.1
function causes impaired ﬁring of GABAergic interneurons rel-
ative to pyramidal cells. Actually, the most supported hypothesis
is that dysfunction of GABAergic interneurons may account both
for recurrent seizures and for cognitive defects/autistic behaviors.
Indeed, GABAergic neurons serve a complex role in normal brain
functions: beyond balancing excitation with inhibition, they are
pivotal for the temporal coordination of neural activity subserv-
ing cognitive functions (Fuchs et al., 2007; Bender et al., 2012).
Therefore, the cognitive impairment is likely not only attributable
to brain injury due to severe and recurrent seizure, but also to an
anomalous functioning of cortical interneurons. Examples may
include alterations in theta and gamma oscillations, and loss of
coordination of pyramidal cell ensembles involved in information
processing (Bender et al., 2012). A new literature is now under
way, linking cognitive abnormalities in different diseases directly
to indices of structural, functional, metabolic, and other neu-
robiological markers of cerebral integrity, independent of their
association with clinical epilepsy features (Hermann et al., 2008).
In addition and no less important, the biological maturity of
interneurons parallels Nav1.1 expression increase during develop-
ment, indicating the importance of this (and others) ion channel
for setting brain networks during growth. This can be also the
case for Kir4.1 mutations in children affected by epilepsy and
ASDs. An abnormal functioning of the astrocyte-neuron synapse
during development can account for the overlapping phenotype
observed in these patients (Sicca et al., 2011). As well, alteration
of cortical interneurons activity during development supports
one current pathophysiological view of schizophrenia (O’Donnell,
2012). This ﬁnding holds up the assumption that the disruption of
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a speciﬁc brain circuitry due to ion channels defects (but also due
to other causes) during development may account for the psychi-
atric disease susceptibility or progression. Indeed, dysregulation of
activity-dependent signaling pathways controlling synaptic func-
tion and allowing neuronal circuits to respond dynamically to
experience, may have a key role in the etiology of ASD (Ebert and
Greenberg, 2013).
Further studies are necessary to fully characterize the exact
composition of ion channels complexes as well as their speciﬁc
cellular localization and function in the brain. Of particular inter-
est are transgenic technologies that allowed the engineering of
mouse models mimicking different kinds of monogenic heritable
forms of psychiatric disorders. These transgenic models provide
excellent opportunities to explore in detail the cellular and molec-
ular mechanisms underlying mental illness pathology and to test
novel therapeutic intervention.
Indeed, the involvement of ion channels in mental illness rep-
resents an attractive alternative target for the pharmaceutical drug
discovery, committed to overcome the limits of common neu-
ropsychiatric drugs such as the adverse effects and limited respon-
siveness. The recent advent of high-throughput electrophysiology,
as well as the emerging structural information of ion channel pro-
teins, helps pharmaceutical research at identifying selective ion
channel modulators with therapeutic potential in neuropsychi-
atric syndromes. As discussed in this review, the pharmacological
proﬁle of classic calcium channel blockers in psychiatric disorders
has still to be ascertained (Casamassima et al., 2010); instead cal-
cium channel modulators targeting the α2δ subunits are showing
positive results (Valente et al., 2012). Among potassium channels
ligands, particular interest has been devoted to SK channel open-
ers with potential antipsychotic properties. These channels are
indeed involved in the control of ﬁre frequency of dopaminer-
gic neurons, one of the principal neuronal networks disrupted
in schizophrenia (Gargus, 2006). Inhibition of the hippocampal
M-current has been proposed as a general strategy to improve
cognitive performance (Fontan-Lozano et al., 2011); on the other
hand M-current openers in prefrontal cortex and hippocampus
resulted helpful in mouse model of BPD and schizophrenia. These
pre-clinical data indicate that M-current activation restores sev-
eral key signaling pathways in psychosis similarly to standard
drugs, like lithium and valproate (Kristensen et al., 2012). Kir
channels are molecular targets of several antidepressants, thus
suggesting that these channels may contribute to the therapeutic
action (or adverse effect) of these drugs (Ohno et al., 2007; Furu-
tani et al., 2009). In addition, KATP potassium channels openers
have been tested as adjuvant in combination with haloperidol
and clozapine in the treatment of schizophrenia (Sun et al., 2010).
Sodium channels blockers such as typical anticonvulsants display
antidepressant activity (Perucca and Mula, 2013), while common
antidepressants have been shown to block sodium channels, thus
proposing the role of Nav channels in the etiology of depression
(Aldana and Sitges, 2012).
Research efforts are therefore required to improve the genetic
diagnosis of psychiatric disorders, as well as their clinical phe-
notyping and ultimately the design of innovative therapeutic
strategies.
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